pralatrexate
Selected indexed studies
- Pralatrexate for lymphoma. (Aust Prescr, 2019) [PMID:31048945]
- Pralatrexate. (, 2012) [PMID:31643237]
- Pralatrexate for Peripheral T-Cell Lymphoma (PTCL): Chance Only Supports The Prepared Mind. (Anticancer Agents Med Chem, 2023) [PMID:35692151]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Pralatrexate for lymphoma. (2019) pubmed
- Pralatrexate. (2012) pubmed
- Pralatrexate for Peripheral T-Cell Lymphoma (PTCL): Chance Only Supports The Prepared Mind. (2023) pubmed
- Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. (2011) pubmed
- Methotrexate and Pralatrexate. (2015) pubmed
- Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. (2020) pubmed
- Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma. (2013) pubmed
- Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas. (2025) pubmed
- Pralatrexate: an emerging new agent with activity in T-cell lymphomas. (2006) pubmed
- Pralatrexate: basic understanding and clinical development. (2010) pubmed